Trial Profile
Study of denosumab for prevention of osteoporotic fractures in patients with connective tissue diseases receiving very high doses of glucocorticoid
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Nov 2018
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Corticosteroid-induced osteoporosis
- Focus Adverse reactions; Therapeutic Use
- 20 Nov 2018 New trial record
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting